ABC Arbitrage SA Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN

ABC Arbitrage SA purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,970 shares of the biopharmaceutical company’s stock, valued at approximately $1,108,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $226,000. Concurrent Investment Advisors LLC boosted its position in Regeneron Pharmaceuticals by 136.4% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,622 shares of the biopharmaceutical company’s stock worth $852,000 after purchasing an additional 936 shares during the period. MGO One Seven LLC raised its holdings in shares of Regeneron Pharmaceuticals by 28.1% during the 2nd quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 106 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.0% during the second quarter. Sequoia Financial Advisors LLC now owns 1,761 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 3.2%

Shares of REGN opened at $778.97 on Thursday. The firm has a market cap of $81.87 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 2.03 and a beta of 0.40. The company’s fifty day moving average is $759.25 and its two-hundred day moving average is $662.51. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the business posted $12.07 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a $0.94 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,636 shares of company stock worth $2,862,920 over the last ninety days. Insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on REGN. Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. HSBC upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Finally, Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $793.81.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.